EyeControl

EyeControl operates at the intersection of assistive technology, medical devices, digital health, and critical care. Its differentiation is the combination of an eye-tracking wearable, an AI-enabled communication platform, and care-team workflows for people who cannot speak or have severe mobility limitations. The product range spans EyeControl-Home for long-term communication needs and EyeControl-Med for intensive-care and recovery settings, extending beyond a single augmentative and alternative communication device. The company also integrates family messaging, bedside workflows, and remote customization, which gives it a broader care-continuum proposition than a standalone speech-generating aid. As a result, EyeControl’s relative position against established AAC providers, eye-gaze hardware vendors, and ICU communication platforms cannot be quantified confidently. Its $15.3 million in cumulative funding, including a $7.5 million Series A and multiple grants, supports product development but does not by itself establish scale.

EyeControl’s trajectory shows a progression from early assistive-communication development toward specialized clinical applications. Founded in 2016, the company recorded a seed round in 2017 and subsequently accumulated grant support, including $3.49 million in 2018, $750,000 in 2019, and $2.5 million from the European Innovation Council in 2020. Its $7.5 million Series A, announced on Aug 12, 2020 and led by Connecticut Innovations, marked the largest disclosed financing event. Product expansion followed with EyeControl-Pro for delirium in 2022, while patents filed or published between 2021 and 2024 focused on sedation monitoring, patient communication, and patient monitoring. The latest disclosed financing was an $898,195 grant on Sep 15, 2023, bringing total disclosed funding to $15,262,102 across eight rounds. Current hiring for a Software Team Lead suggests ongoing technical investment, and the employee band indicates a small organization of approximately 11–50 people. The main unresolved question is whether clinical validation and hospital adoption have translated into sustained commercial growth; public information does not provide revenue, deployment counts, or employee-growth figures.